<b>Objectives</b>: To explore if MRI can monitor treatment and predict outcome in patients with human epidermal growth factor 2 (HER2)-negative breast cancer receiving neoadjuvant chemotherapy (NACT) with or without bevacizumab. The gene discussed is ERBB2; the disease is breast carcinoma.